published meta-analysis   sensitivity analysis   studies

interferon in COVID-19 severe or critically - Summary of results

OutcomeTE95% CInkI2ROBPub. bias death D28detailed resultsKalil (ACTT-3), 2021 1.74 [0.51; 5.93] 1.74[0.51; 5.93]Kalil (ACTT-3), 202110%969NAnot evaluable deathsdetailed resultsDarazam (COVIFERON Interferon beta-1a), 2021 0.31 [0.07; 1.25] Darazam (COVIFERON Interferon beta-1b), 2021 0.52 [0.14; 1.92] Kalil (ACTT-3), 2021 1.74 [0.51; 5.93] Rahmani, 2020 0.29 [0.05; 1.56] 0.58[0.25; 1.37]Darazam (COVIFERON Interferon beta-1a), 2021, Darazam (COVIFERON Interferon beta-1b), 2021, Kalil (ACTT-3), 2021, Rahmani, 2020434%1,115moderatenot evaluable deaths (time to event analysis only)detailed resultsKalil (ACTT-3), 2021 1.74 [0.51; 5.93] 1.74[0.51; 5.93]Kalil (ACTT-3), 202110%969NAnot evaluable clinical improvementdetailed resultsDarazam (COVIFERON Interferon beta-1a), 2021 2.36 [1.09; 5.12] Kalil (ACTT-3), 2021 0.99 [0.87; 1.13] 1.40[0.61; 3.23]Darazam (COVIFERON Interferon beta-1a), 2021, Kalil (ACTT-3), 2021279%1,009moderatenot evaluable clinical improvement (14-day)detailed resultsKalil (ACTT-3), 2021 1.01 [0.79; 1.29] 1.01[0.79; 1.29]Kalil (ACTT-3), 202110%969NAnot evaluable clinical improvement (time to event analysis only)detailed resultsDarazam (COVIFERON Interferon beta-1a), 2021 2.36 [1.09; 5.12] Darazam (COVIFERON Interferon beta-1b), 2021 1.42 [0.63; 3.18] Kalil (ACTT-3), 2021 0.99 [0.87; 1.13] Rahmani, 2020 3.41 [1.33; 8.73] 1.66[0.90; 3.06]Darazam (COVIFERON Interferon beta-1a), 2021, Darazam (COVIFERON Interferon beta-1b), 2021, Kalil (ACTT-3), 2021, Rahmani, 2020474%1,115moderatenot evaluable hospital dischargedetailed resultsRahmani, 2020 3.44 [0.64; 18.49] 3.44[0.64; 18.49]Rahmani, 202010%66NAnot evaluable mechanical ventilationdetailed resultsDarazam (COVIFERON Interferon beta-1a), 2021 1.00 [0.27; 3.67] Darazam (COVIFERON Interferon beta-1b), 2021 1.00 [0.27; 3.67] Rahmani, 2020 0.29 [0.05; 1.56] 0.75[0.34; 1.69]Darazam (COVIFERON Interferon beta-1a), 2021, Darazam (COVIFERON Interferon beta-1b), 2021, Rahmani, 202030%146moderatenot evaluable ICU admissiondetailed resultsDarazam (COVIFERON Interferon beta-1a), 2021 1.00 [0.21; 4.71] Darazam (COVIFERON Interferon beta-1b), 2021 0.46 [0.11; 1.94] Rahmani, 2020 0.37 [0.14; 1.00] 0.49[0.24; 1.00]Darazam (COVIFERON Interferon beta-1a), 2021, Darazam (COVIFERON Interferon beta-1b), 2021, Rahmani, 202030%146moderatenot evaluable superinfectiondetailed resultsRahmani, 2020 0.18 [0.02; 1.59] 0.18[0.02; 1.59]Rahmani, 202010%66NAnot evaluable0.05.01.0relative treatment effectwww.metaEvidence.org2024-03-28 18:42 +01:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 91 - treatments: 517,881,904,882,897,896,899,1235,898,687,740,883,947 - roots T: 290